Abevmy (bevacizumab) 25 mg/mL concentrate for solution for infusion. Available In India.

Abevmy (bevacizumab) injection suppliers in India. Indian Pharma Network (IPN) New Delhi, INDIA.

IPN is a facilitator under Patient Assistance Programs. Expertise in Specialty Pharmaceutical distribution having its PAN India presence in Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, lucknow, north East and Pune and other cities in India. with over 20 years of domain experience.

For procurement cost of Abevmy (bevacizumab) injection brand in India, sold by indian drug manufacturer. Please call at M: +91 9811747774 (Mr. Tarun) / 9891296838 (Mr. Neeraj) or Email Us to know more details about the Abevmy (bevacizumab) injection tablets cost price in India.

The order for Abevmy (bevacizumab) injection will be confirmed only after the receipt of valid prescription of doctor and import permit if applicable.

MEDICAL USES
Covid19
Studies going on to treat for Covid19 Patients.
Colorectal cancer
Bevacizumab was approved in the United States in February 2004, for use in metastatic colorectal cancer.
Lung cancer
In 2006, the U.S. Food and Drug Administration (FDA) approved bevacizumab for use in first-line advanced nonsquamous non-small cell lung cancer in combination with carboplatin/paclitaxel chemotherapy.
Breast cancer
In December 2010, the U.S. Food and Drug Administration (FDA) notified its intention to remove the breast cancer indication from bevacizumab.
Renal cancers
In 2009, the FDA approved bevacizumab for use in metastatic renal cell cancer (a form of kidney cancer). EU approval was granted in 2007. In the EU, bevacizumab in combination with interferon alfa-2a is indicated for first-line treatment of adults with advanced and/or metastatic renal cell cancer.
Brain cancers
The FDA granted accelerated approval for the treatment of recurrent glioblastoma multiforme in May 2009.
Eye disease
Many diseases of the eye, such as age-related macular degeneration (AMD) and diabetic retinopathy, damage the retina and cause blindness when blood vessels around the retina grow abnormally and leak fluid, causing the layers of the retina to separate. This abnormal growth is caused by VEGF, so bevacizumab has been successfully used to inhibit VEGF and slow this growth.
Ovarian cancer
In 2018, the U.S. Food and Drug Administration (FDA) approved bevacizumab in combination with chemotherapy for stage III or IV of ovarian cancer after initial surgical operation, followed by single-agent bevacizumab.
Cervical cancer
In the EU, bevacizumab, in combination with paclitaxel and cisplatin or, alternatively, paclitaxel and topotecan in people who cannot receive platinum therapy, is indicated for the treatment of adults with persistent, recurrent, or metastatic carcinoma of the cervix.

Abevmy (bevacizumab) injection tablets, for oral use. Initial U.S. Approval: 2004

Generic Name: bevacizumab

• 100 mg/4 mL, single use vial
• 400 mg/16 mL, single use vial.